Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents

Table 3 Adverse events

Adverse event	Saxagliptin n = 68	Vildagliptin n = 63	Sitagliptin n = 63	P value
Edema	1(2%)	0(0%)	1(2%)	0.60
Headache	0(0%)	1(2%)	1(2%)	0.58
Elevated liver enzymes	2(3%)	3(5%)	2(3%)	0.86
Symptomatic hypoglycemia	4(6%)	1(2%)	2(3%)	0.41
Abdominal discomfort	3(4%)	5(8%)	3(5%)	0.64
Diarrhea	3(4%)	1(2%)	3(5%)	0.57
Chest discomfort & dyspnea	2(3%)	2(3%)	2(3%)	0.99
Nasosinusitis	5(7%)	0(0%)	6(10%)	0.053
Total	20(29%)	13(21%)	20(32%)

Data are presented as number (%). χ² test and Fisher’s exact test were used for comparison of differences in the three groups.

ISSN: 1758-5996